Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

The World Health Organization's COVID-19 Technology Access Pool (C-TAP) initiative has entered into a nonexclusive sublicense agreement with Biotech Africa to manufacture a serology assay to detect previous SARS-CoV-2 infection.

On June 9, 2022, Siemens Healthineers China officially released the company's new "National Intelligence Innovation" localization strategy, announcing that it will deeply participate in Healthy China construction as a "Chinese company" through three demensions.

Thermo Fisher Scientific said on Wednesday that it has received CE-IVD marking for its Ion Torrent Reporter Software Aneuploidy Dx Workflows.

Roche said on Wednesday that the US Food and Drug Administration has issued Emergency Use Authorization for the Cobas SARS-CoV-2 Duo assay.

On June 11, 2022, the signing ceremony of the strategic cooperation between Zhengzhou Autobio Diagnostics Co., Ltd. and Pro-med (Beijing) Technology Co., Ltd. was held in Zhengzhou, and the two parties officially launched the strategic cooperation.

Digital pathology company Proscia announced on Tuesday that it has raised $37 million in a Series C financing round.

Sophia Genetics said that it has received CE-IVD marking for analytics functionality of its core Sophia Data Driven Medicine (DDM) software platform. The Swiss-American firm made the announcement Tuesday at the European Society of Human Genetics conference in Vienna.

Currently, there is a shortage of monkeys in the china pharmaceutical industry, and pharmaceutical R & D enterprises are purchasing lab monkeys on a large scale.

The US Food and Drug Administration announced after the close of the markets on Friday that it has issued Emergency Use Authorization (EUA) for Laboratory Corporation of America's VirSeq SARS-CoV-2 NGS Test.

OncoHost will use SomaLogic's SomaScan platform to develop proteomic tests for OncoHost's Prophet diagnostic system to predict patient response to immunotherapy treatments and develop strategies to overcome treatment resistance, the two firms announced on Monday.